MedTrace Logo

The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study

NCT00953667 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2016-03-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine genetic factors that affect responses to niacin therapy and endotoxemia in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Immediate Release Niacin, Extended Release Niacin, Endotoxin

Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).

Sponsors & Collaborators

Principal Investigators

  • Muredach P Reilly, M.B., MSCE · University of Pennsylvania

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953667 on ClinicalTrials.gov